52 filings
424B3
LXEO
Lexeo Therapeutics Inc.
9 May 24
Prospectus supplement
7:09am
8-K
LXEO
Lexeo Therapeutics Inc.
9 May 24
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
7:07am
10-Q
2024 Q1
LXEO
Lexeo Therapeutics Inc.
Quarterly report
9 May 24
7:02am
ARS
2023 FY
LXEO
Lexeo Therapeutics Inc.
26 Apr 24
Annual report to shareholders
7:57am
DEFA14A
LXEO
Lexeo Therapeutics Inc.
26 Apr 24
Additional proxy soliciting materials
7:56am
DEF 14A
7skbs
26 Apr 24
Definitive proxy
7:55am
424B3
cmpksvgotjwhy8v9c
22 Apr 24
Prospectus supplement
8:24am
424B3
jw2w9
22 Apr 24
Prospectus supplement
8:23am
8-K
1q8fp pcd7jj
22 Apr 24
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
8:22am
8-K
5soq2d72e 92
22 Apr 24
Departure of Directors or Certain Officers
8:11am
424B3
613 z2c7u
16 Apr 24
Prospectus supplement
7:35am
8-K
7h0n1n1eiws
16 Apr 24
Other Events
7:32am
EFFECT
vuz5l9o2dq94w
15 Apr 24
Notice of effectiveness
12:15am
424B3
zan9 2shwzr0fwmjh9nu
12 Apr 24
Prospectus supplement
5:04pm
8-K
4we3e qfy
11 Mar 24
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
4:11pm
S-8
6dvqgwf8kxlrwz16xs
11 Mar 24
Registration of securities for employees
4:09pm
10-K
94ad1ymj3713
11 Mar 24
Annual report
9:29am
8-K
kk2r3fv eh50pn6j5xcf
5 Feb 24
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
7:03am
8-K
hehtoqp 4t
18 Dec 23
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an
7:00am